Patents by Inventor Nathalie RIOUX

Nathalie RIOUX has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapies for the treatment of breast cancer
    Patent number: 11083722
    Abstract: Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: August 10, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Craig D. Karr, Manav Korpal, Nathalie Rioux, Peter Gerard Smith
  • COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20210113537
    Abstract: Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor.
    Type: Application
    Filed: March 16, 2018
    Publication date: April 22, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Craig D. KARR, Manav KORPAL, Nathalie RIOUX, Peter Gerard SMITH
  • TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20200255415
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: November 22, 2017
    Publication date: August 13, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu, Lorna Helen Mitchell, Nicholas Larsen, Nathalie Rioux, Sudeep Prajapati, Dominic Reynolds, Morgan O'Shea, Thiwanka Samarakoon
  • TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE
    Publication number: 20190337921
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: November 22, 2017
    Publication date: November 7, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu, Lorna Helen Mitchell, Nicholas Larsen, Nathalie Rioux
  • TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE
    Publication number: 20180141913
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: November 22, 2017
    Publication date: May 24, 2018
    Applicant: EISAI R & D MANAGEMENT CO., LTD.
    Inventors: Mark BOCK, Ming-Hong HAO, Manav KORPAL, Vijay Kumar NYAVANANDI, Xiaoling PUYANG, Susanta SAMAJDAR, Peter Gerard SMITH, John WANG, Guo Zhu ZHENG, Ping ZHU, Lorna Helen MITCHELL, Nicholas LARSEN, Nathalie RIOUX, Sudeep PRAJAPATI, Dominic REYNOLDS, Morgan O'SHEA, Thiwanka SAMARAKOON